1365-2036/asset/olbannerleft.gif?v=1&s=45db8c78d1d41c404034f2eaf7587620d5727843)
1365-2036/asset/olbannerright.gif?v=1&s=45518840b7e2e59fcc9d74113b13f4474a604878)
You have free access to this content
Randomised clinical trial: escitalopram for the prevention of psychiatric adverse events during treatment with peginterferon-alfa-2a and ribavirin for chronic hepatitis C
Article first published online: 17 OCT 2011
DOI: 10.1111/j.1365-2036.2011.04867.x
© 2011 Blackwell Publishing Ltd
Additional Information
How to Cite
de Knegt, R. J., Bezemer, G., Van Gool, A. R., Drenth, J. P. H., Hansen, B. E., Droogleever Fortuyn, H. A., Weegink, C. J., Hengeveld, M. W. and Janssen, H. L. A. (2011), Randomised clinical trial: escitalopram for the prevention of psychiatric adverse events during treatment with peginterferon-alfa-2a and ribavirin for chronic hepatitis C. Alimentary Pharmacology & Therapeutics, 34: 1306–1317. doi: 10.1111/j.1365-2036.2011.04867.x
Publication History
- Issue published online: 16 NOV 2011
- Article first published online: 17 OCT 2011
- Publication data Submitted 3 April 2011 First decision 22 April 2011 Resubmitted 4 September 2011 Accepted 5 September 2011 EV Pub Online 17 October 2011
Corrected by:
CORRIGENDA: Corrigenda
Vol. 35, Issue 7, 864, Article first published online: 8 MAR 2012
References
- 1, . Hepatitis C virus infection. N Engl J Med 2001; 345: 41–52.
- 2, , , et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958–65.
- 3, , , et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975–82.
- 4, , , et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346–55.
- 5, , , et al. Irritability rather than depression during interferon treatment is linked to increased tryptophan catabolism. Psychosom Med 2005; 67: 773–7.
- 6. Side effects of alpha interferon in chronic hepatitis C. Hepatology 1997; 26: 112S–21S.
- 7, , . Interferon-induced depression and cognitive impairment in hepatitis C virus patients: a 72 week prospective study. AIDS 2005; 19(Suppl. 3): S174–8.
- 8, , , et al. Cognitive impairment in patients with chronic hepatitis treated with interferon alpha (IFNalpha): results from a prospective study. Eur Psychiatry 2006; 21: 204–10.
- 9, , , et al. Immunotherapy with interferon-alpha in patients affected by chronic hepatitis C induces an intercorrelated stimulation of the cytokine network and an increase in depressive and anxiety symptoms. Psychiatry Res 2001; 105: 45–55.
- 10, , , , . Treatment with interferon-alpha in patients with chronic hepatitis and mood or anxiety disorders. Lancet 1999; 354: 131–2.
- 11, , , et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002; 123: 1061–9.
- 12, , , et al. A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. Mol Psychiatry 2002; 7: 942–7.
- 13, , , et al. Therapy of interferon-induced depression in chronic hepatitis C with citalopram: a randomised, double-blind, placebo-controlled study. Gut 2008; 57: 531–6.
- 14American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders 2000, DSM-IV TR. Arlington, USA: American Psychiatric Publishing, 2000.
- 15World Health Organisation, ICD Version 2007. Available at: http://apps.who.int/classifications/apps/icd/icd10online.
- 16, , , et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998; 20: 22–33.
- 17, . A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134: 382–9.
- 18, , . The brief scale for anxiety: a subdivision of the comprehensive psychopathological rating scale. J Neurol Neurosurg Psychiatry 1984; 47: 970–5.
- 19, , . Psychometric properties of the Beck Depression Inventory: twenty-five years of evaluation. Clin Psychol Rev 1988; 8: 77–100.
- 20
- 21, . Interferon-induced depression in chronic hepatitis C: a review of its prevalence, risk factors, biology and treatment approaches. J Clin Gastroenterol 2006; 40: 322–35.
- 22, , , et al. Evaluation of depression as a risk factor for treatment failure in chronic hepatitis C. Hepatology 2010; 52: 430–5.
- 23, , , et al. Adherence and mental side-effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology 2003; 37: 443–51.
- 24, , , . Prophylactic SSRI during interferon alpha re-therapy in patients with chronic hepatitis C and a history of interferon-induced depression. J Viral Hepat 2005; 12: 96–100.
- 25, , , et al. Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C. J Hepatol 2005; 42: 793–8.
- 26, , , . Preventing relapse of major depression during interferon-alpha therapy for hepatitis C – a pilot study. Dig Dis Sci 2007; 52: 2557–63.
- 27, , , et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med 2001; 344: 961–6.
- 28, , , , , . A randomized trial of paroxetine to prevent interferon-alpha-induced depression in patients with hepatitis C. J Affect Disord 2007; 103: 83–90.
- 29, , , et al. Prophylactic antidepressant treatment in patients with hepatitis C on antiviral therapy: a double-blind, placebo-controlled trial. Psychosomatics 2010; 51: 401–8.
- 30, , , et al. Paroxetine for prevention of depressive symptoms induced by interferon alpha and ribavirin for hepatitis C. Aliment Pharmacol Ther 2007; 25: 1163–74.
- 31, , , et al. De novo depression and anxiety disorders and influence on adherence during peginterferon-alpha-2a and ribavirin treatment in patients with hepatitis C. Aliment Pharmacol Ther 2008; 27: 257–65.
- 32, . The onset of effect for escitalopram and its relevance for the clinical management of depression. Curr Med Res Opin 2006; 22: 2101–10.
- 33, , . Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 2002; 17: 95–102.
- 34, , . Escitalopram (10–20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 2003; 18: 211–7.
- 35, , . Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis. J Psychiatry Neurosci 2006; 31: 122–31.
- 36, , , , , . Physical and psychosocial contributors to quality of life in veterans with hepatitis C not on antiviral therapy. J Clin Gastroenterol 2005; 39: 731–6.
- 37, , , . Investigating health-related quality of life, mood and neuropsychological test performance in a homogeneous cohort of Irish female hepatitis C patients. J Viral Hepat 2010; 17: 352–9.
- 38, , , . A prospective study of neuropsychiatric symptoms associated with interferon-α-2b and ribavirin therapy for patients with chronic hepatitis C. Psychosomatics 2003; 44: 104–12.